亞士創能(603378.SH):向特定對象發行股票註冊批覆到期失效
格隆匯9月18日丨亞士創能(603378.SH)公佈,公司於2023年9月18日收到中國證券監督管理委員會出具的《關於同意亞士創能科技(上海)股份有限公司向特定對象發行股票註冊的批覆》,同意公司向特定對象發行股票的註冊申請,本批覆自同意註冊之日(2023年9月15日)起12個月內有效。公司在取得批覆後一直積極推進本次向特定對象發行股票的各項工作,由於資本市場環境和融資時機等多方面因素變化,公司未能在批覆的有效期內實施本次向特定對象發行股票事宜,該批覆到期自動失效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.